Evidence map›Paper›PMID 30089166›Full record

ArticlePloS one2018

Presenilin1 regulates Th1 and Th17 effector responses but is not required for experimental autoimmune encephalomyelitis.

Matthew Cummings, Anitha Christy Sigamani Arumanayagam, Picheng Zhao, Sunil Kannanganat, Olaf Stuve, Nitin J Karandikar, Todd N Eagar

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 7 citations in OpenAlex.

  1. Article
  2. Article
  3. TemporalACS omega · 2020
    Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Matthew CummingsDepartment of Pathology, University of Texas Southwestern Medical Center, Dallas, TX, United States of America.
Anitha Christy Sigamani ArumanayagamDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital Research Institute, Houston, TX, United States of America.
Picheng ZhaoDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital Research Institute, Houston, TX, United States of America.
Sunil KannanganatDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital Research Institute, Houston, TX, United States of America.
Olaf StuveNeurology Section, VA North Texas Health Care System, Medical Service, Dallas, TX, United States of America.
Nitin J KarandikarDepartment of Pathology, University of Iowa, Iowa City, IA, United States of America.
Todd N EagarDepartment of Pathology and Genomic Medicine, Houston Methodist Hospital Research Institute, Houston, TX, United States of America.ORCID 0000-0002-9738-544X
Methodist Hospital · USThe University of Texas Southwestern Medical Center · USUniversity of Iowa · USVA North Texas Health Care System · US

Funding

Modulating B and T cell functions in EAE through gamma secretase and NotchR01NS081237 · NINDS · METHODIST HOSPITAL RESEARCH INSTITUTE · PI EAGAR, TODD N · 2013 to 2017
$1.4M
NINDS NIH HHS R01 NS081237
6 · The paper itself

Abstract

Multiple Sclerosis (MS) is an inflammatory demyelinating disease of the central nervous system (CNS) where pathology is thought to be regulated by autoreactive T cells of the Th1 and Th17 phenotype. In this study we sought to understand the functions of Presenilin 1 (PSEN1) in regulating T cell effector responses in the experimental autoimmune encephalomyelitis (EAE) murine model of MS. PSEN1 is the catalytic subunit of γ-secretase a multimolecular protease that mediates intramembranous proteolysis. γ-secretase is known to regulate several pathways of immune importance. Here we examine the effects of disrupting PSEN1 functions on EAE and T effector differentiation using small molecule inhibitors of γ-secretase (GSI) and T cell-specific conditional knockout mice (PSEN1 cKO). Surprisingly, blocking PSEN1 function by GSI treatment or PSEN1 cKO had little effect on the development or course of MOG35-55-induced EAE. In vivo GSI administration reduced the number of myelin antigen-specific T cells and suppressed Th1 and Th17 differentiation following immunization. In vitro, GSI treatment inhibited Th1 differentiation in neutral but not IL-12 polarizing conditions. Th17 differentiation was also suppressed by the presence of GSI in all conditions and GSI-treated Th17 T cells failed to induce EAE following adoptive transfer. PSEN cKO T cells showed reduced Th1 and Th17 differentiation. We conclude that γ-secretase and PSEN1-dependent signals are involved in T effector responses in vivo and potently regulate T effector differentiation in vitro, however, they are dispensable for EAE.

Indexed as

Amyloid Precursor Protein SecretasesAnimalsCell DifferentiationCell ProliferationDibenzazepinesEncephalomyelitis, Autoimmune, ExperimentalFemaleGranulocyte-Macrophage Colony-Stimulating FactorInterleukin-17Interleukin-2MiceMice, Inbred C57BLMice, KnockoutNuclear Receptor Subfamily 1, Group F, Member 3Presenilin-1Th17 CellsAmyloid Precursor Protein SecretasesdibenzazepineDibenzazepinesGranulocyte-Macrophage Colony-Stimulating FactorInterleukin-17Interleukin-2Nuclear Receptor Subfamily 1, Group F, Member 3Presenilin-1

Identifiers

PMID30089166
PMCPMC6082653
OpenAlexW2886543220

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.